Evidence map›Paper›PMID 37183460›Full record

ReviewCurrent medicinal chemistry2024

The Development of Non-natural Type Nucleoside to Stabilize Triplex DNA Formation against CG and TA Inversion Site.

Lei Wang, Yong Ling, Yan Tian, Xiao Wang, Shigeki Sasaki, Yosuke Taniguchi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Lei WangSchool of Pharmacy, Nantong University, Nantong, China.
Yong LingSchool of Pharmacy, Nantong University, Nantong, China.
Yan TianSchool of Pharmacy, Nantong University, Nantong, China.
Xiao WangSchool of Pharmacy, Nantong University, Nantong, China.
Shigeki SasakiGraduate School of Pharmaceutical Sciences, Nagasaki International University, Nagasaki City, Japan.
Yosuke TaniguchiGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Nantong University · CNKyushu University · JPNagasaki International University · JP

Funding

Japan Society for the Promotion of Science (JSPS), JP19H03351; JP21am0401026
6 · The paper itself

Abstract

Based on the sequence-specific recognition of target duplex DNA by triplexforming oligonucleotides (TFOs) at the major groove side, the antigene strategy has been exploited as a gene-targeting tool with considerable attention. Triplex DNA is formed via the specific base triplets by the Hoogsteen or reverse Hoogsteen hydrogen bond interaction between TFOs and the homo-purine strand from the target duplex DNA, leading to the established sequence-specificity. However, the presence of inversion sites, which are known as non-natural nucleosides that can form satisfactory interactions with 2'- deoxythymidine (dT) and 2'-deoxycytidine (dC) in TA and CG base pairs in the target homo-purine DNA sequences, drastically restricts the formation of classically stable base triplets and even the triplex DNA. Therefore, the design of non-natural type nucleosides, which can effectively recognize CG or/and TA inversion sites with satisfactory selectivity, should be of great significance to expanding the triplex-forming sequence. Here, this review mainly provides a comprehensive review of the current development of novel nonnatural nucleosides to recognize CG or/and TA inversion sites in triplex DNA formation against double-strand DNA (dsDNA).

Indexed as

DNANucleosidesBase PairingHumansNucleic Acid ConformationDNANucleosidestriplex DNAantigene strategydeoxythymidine.inversion sitenon-natural nucleotiderecognitiontriplex DNATriplex-forming oligonucleotide (TFO)

Identifiers

PMID37183460
OpenAlexW4376570017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.